Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02506192 · ClinicalTrials.gov registry record · Phase 2
Gulf War Illness Inflammation Reduction Trial
A Phase 2 study of Chronic Pain and Fatigue, sponsored by Minneapolis Veterans Affairs Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT02506192: Completed Phase 2 study of Chronic Pain and Fatigue, sponsored by Minneapolis Veterans Affairs Medical Center.
NCT02506192 is a Phase 2 study of Chronic Pain and Fatigue that has completed, run by Minneapolis Veterans Affairs Medical Center. The registered enrollment target is 83 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02506192, a Phase 2 study of Chronic Pain and Fatigue, has completed, sponsored by Minneapolis Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this clinical trial is to determine if treatment with an anti-inflammatory drug (delayed-release prednisone) improves the health-related quality of life (HRQOL) of veterans with Gulf War Illness (GWI). The primary outcome measure is a change from baseline of HRQOL with respect to physical functioning and symptoms. Secondary outcomes measures include changes from baseline levels of GWI-associated biomarkers of inflammation in peripheral blood, GWI-associated symptoms (chronic pain, fatigue, and cognitive impairment), and HRQOL with respect to mental functioning.
Primary Outcome
The SF-36V is a modification of the well-established Medical Outcomes Study Short Form Health Survey (SF-36). It surveys eight concepts of health: physical functioning, role limitations because of physical problems, bodily pain, general health perceptions, energy/vitality, social functioning, role limitations due to emotional problems and mental health. From these concepts, two summary component scores are derived: a Physical Component Summary (PCS) and a Mental Component Summary (MCS). To calc
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Modified-Release Prednisone
Study Locations (1)
Minnesota
- Minneapolis Veterans Affairs Medical Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2015-07 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 2 |
What the finished NCT02506192 record still lists
NCT02506192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (89% lower).
The record links to 4 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02506192 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02506192 about?
NCT02506192 is a clinical study titled "Gulf War Illness Inflammation Reduction Trial". The primary objective of this clinical trial is to determine if treatment with an anti-inflammatory drug (delayed-release prednisone) improves the health-related quality of life (HRQOL) of veterans with Gulf War Illness (GWI). The primary outcome measure is a change from baseline of HRQOL with respe...
What is the current status of trial NCT02506192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2015-07. Estimated completion is 2023-10-19.
What conditions does trial NCT02506192 study?
This clinical trial studies the following conditions: Chronic Pain, Fatigue, Cognitive Impairment, Chronic Inflammation.
What interventions are being tested in trial NCT02506192?
The interventions under investigation include: Placebo (DRUG), Modified-Release Prednisone (DRUG).
Who is sponsoring clinical trial NCT02506192?
This trial is sponsored by Minneapolis Veterans Affairs Medical Center, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02506192 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02506192's enrollment target sits among peer trials
83 149th of 301 higher than 153 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia